Juliette Berangere Audet - May 1, 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Strategy and Business Officer
Signature
/s/ Juliette Berangere Audet
Stock symbol
NAMS
Transactions as of
May 1, 2025
Transactions value $
$0
Form type
4
Date filed
5/2/2025, 04:56 PM
Previous filing
Jan 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Audet Juliette Berangere Chief Strategy and Business Officer C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Juliette Berangere Audet 2025-05-02 0002000393

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +30K $0.00 30K May 1, 2025 Ordinary Shares 30K $20.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option will vest on May 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through such date.

Remarks:

Chief Strategy and Business Officer